BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28030859)

  • 1. Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
    Kawaguchi Y; Hanaoka J; Hayashi H; Mizusaki N; Iihara H; Itoh Y; Sugiyama T
    Chemotherapy; 2017; 62(3):147-150. PubMed ID: 28030859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
    Tamiya A; Tamiya M; Nishihara T; Shiroyama T; Nakao K; Tsuji T; Takeuchi N; Isa SI; Omachi N; Okamoto N; Suzuki H; Okishio K; Iwazaki A; Imai K; Hirashima T; Atagi S
    Anticancer Res; 2017 Aug; 37(8):4177-4182. PubMed ID: 28739703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
    Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
    J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
    Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
    Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis.
    Lin CH; Lin MT; Kuo YW; Ho CC
    Lung Cancer; 2014 Sep; 85(3):479-80. PubMed ID: 24999085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
    Tamiya M; Shiroyama T; Nishihara T; Nishida T; Hayama M; Tanaka A; Morishita N; Suzuki H; Okamoto N; Hirashima T
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e531-e533. PubMed ID: 28004883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
    Nakamichi S; Kubota K; Horinouchi H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Tamura T
    Jpn J Clin Oncol; 2013 Apr; 43(4):422-5. PubMed ID: 23410901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
    Kuiper JL; Smit EF
    Lung Cancer; 2013 Apr; 80(1):102-5. PubMed ID: 23375403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
    Tanaka H; Inomata M; Hayashi R; Shimokawa K; Tokui K; Okazawa S; Kambara K; Yamada T; Miwa T; Kashii T; Konishi H; Tobe K
    Gan To Kagaku Ryoho; 2017 Jul; 44(7):595-597. PubMed ID: 28790264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
    Ghosn M; Assi T; El Rassy E; Moussa T; Kattan J
    Bull Cancer; 2017 Apr; 104(4):385-387. PubMed ID: 28131317
    [No Abstract]   [Full Text] [Related]  

  • 11. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
    Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS
    J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature.
    How J; Mann J; Laczniak AN; Baggstrom MQ
    Clin Lung Cancer; 2017 Jul; 18(4):354-363. PubMed ID: 28245967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Leptomeningeal Carcinomatosis: Review of 2 Cases.
    Grimsrud KW; Mrugala MM
    Neurologist; 2019 Mar; 24(2):59-61. PubMed ID: 30817492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
    Masuda T; Hattori N; Hamada A; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Kohno N
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1465-9. PubMed ID: 21274533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
    Gong L; Xiong M; Huang Z; Miao L; Fan Y
    Lung Cancer; 2015 Sep; 89(3):268-73. PubMed ID: 26141219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.
    Liao BC; Lee JH; Lin CC; Chen YF; Chang CH; Ho CC; Shih JY; Yu CJ; Yang JC
    J Thorac Oncol; 2015 Dec; 10(12):1754-61. PubMed ID: 26334749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.
    Wada Y; Koyama S; Kuraishi H; Miyahara T; Yoshiike F; Agatsuma T; Yamamoto R; Ono Y; Suzuki T; Hachiya T; Gomi D; Tateishi K; Hanaoka M; Koizumi T
    Respir Investig; 2016 Nov; 54(6):462-467. PubMed ID: 27886858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.
    Kashima J; Okuma Y; Miwa M; Hosomi Y
    Jpn J Clin Oncol; 2017 Apr; 47(4):357-362. PubMed ID: 28064206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.